Intellectual Property Office
Non-Confidential Disclosures
“Inhibition of Hepatitis B Virus Reverse Transcriptase by Porphyrin-Based Compounds ”
PSU Invention Disclosure Number 2007-3353
Field of the Invention:
Inhibition of Hepatitis B Virus Reverse Transcriptase by Porphyrin-Based Compounds
Inventors:
Jianming Hu, M.D., Ph.D., Li Lin, Ph.D.
Patent status:
Patent Pending
Background:
Chronic Hepatitis B viral infections affect over 350,000,000 patients worldwide and dramatically increase the risk of liver cirrhosis and liver cancer. Although recent studies indicate that antiviral therapy can slow or prevent cancer in HBV-infected patients, current therapies for chronic HBV infections are ineffective in 70-80% of patients. Clearly, more effective treatment options are urgently needed for the millions of patients suffering from this disease.
Invention description:
We have discovered a potent, novel class of compounds that block a very early step in the HBV life cycle. These compounds are directed at an entirely different viral target from current anti-HBV agents and work through an entirely novel mechanism of action that has not been exploited for anti-HBV treatment. Our compounds are an ideal choice for strains of HBV that have developed drug resistance to current therapies.
Advantages:
- Novel mechanism of action
- Directed at a novel viral target
- .Effective against viral mutants that are resistant to current anti-HBV drugs
Contact:
Dr. James F. Kolonay, Ph.D.
Technology Licensing Officer
Intellectual Property Office
The Pennsylvania State University
113 Technology Center
University Park, PA 16802-7000
Phone: (814) 863-7070
Fax: (814) 865-3591
E-mail: jfk11@psu.edu
|
